A small molecule TGF-β inhibitor, pirfenidone (Esbriet®), has been approved as an agent for idiopathic pulmonary fibrosis in several countries and is currently one of the leading anti-fibrotic drugs in the field [159]. The gene discussed is TGFB1; the disease is pulmonary fibrosis.